This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Forma Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Key information
-53.2%
Earnings growth rate
40.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -45.9% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Rate
Aug 30
Forma Therapeutics GAAP EPS of -$1.10 misses by $0.11
Aug 05We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Mar 04We're Hopeful That Forma Therapeutics Holdings (NASDAQ:FMTX) Will Use Its Cash Wisely
Nov 20Here's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
Aug 13We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Needs To Drive Business Growth Carefully
Apr 18What Type Of Shareholders Own The Most Number of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Shares?
Jan 03Forma Therapeutics closes public offering priced at $45.25
Dec 16Forma Therapeutics prices equity offering at $45.25
Dec 11Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation
Dec 08Forma Therapeutics EPS beats by $0.01
Nov 12Forma Therapeutics' sickle cell candidate an orphan drug in Europe
Nov 10Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Forma Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 0 | -190 | 53 | 11 |
| 31 Mar 22 | 0 | -181 | 52 | 0 |
| 31 Dec 21 | 0 | -173 | 48 | 0 |
| 30 Sep 21 | 0 | -151 | 43 | 54 |
| 30 Jun 21 | 0 | -136 | 38 | 54 |
| 31 Mar 21 | 0 | -119 | 32 | 0 |
| 31 Dec 20 | 0 | -74 | 31 | 0 |
| 30 Sep 20 | 7 | -74 | 30 | 0 |
| 30 Jun 20 | 11 | -78 | 29 | 0 |
| 31 Mar 20 | 29 | -61 | 28 | 0 |
| 31 Dec 19 | 101 | -53 | 24 | 0 |
| 31 Dec 18 | 164 | 0 | 22 | 0 |
Quality Earnings: FMTX is currently unprofitable.
Growing Profit Margin: FMTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FMTX is unprofitable, and losses have increased over the past 5 years at a rate of 53.2% per year.
Accelerating Growth: Unable to compare FMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: FMTX has a negative Return on Equity (-45.88%), as it is currently unprofitable.